KRAS and non-small cell lung carcinoma: The acquisition of KRAS mutations in EGFR mutant NSCLC patients following treatment with first line EGFR TKIs has recently been reported (Del Re et al.), although these mutations have not been detected in other similar first line cohorts10,11,23,24'.